fbpx
CAS Insight

molecules of the month

T-690

oral GCS inhibitor

Preclinical, neurodegeneration

scaffold hop from prev. reported GCS inhibitor

J. Med. Chem.

Takeda

oral GCS inhibitor - Takeda
3 mins read

Context. T-690 (Takeda) is an oral GCS inhibitor that is brain-penetrant, non-basic, and non-competitive with UDP-glucose. We recently highlighted a glucosylceramide synthase (GCS, aka CGT) inhibitor in Ph. III (Sanofi’s venglustat). GCS inhibition may reduce glycosphingolipid levels downstream of its product, glucosylceramide (GlcCer). GCS inhibitors have been clinically explored in diseases where accumulation of glycosphingolipids may contribute to pathology, including GBA-mutant Parkinson’s disease and various rare genetic diseases. The Takeda molecule has a distinct structure from previously reported GCS inhibitors (Eliglustat, EXEL-0346, venglustat and BZ1). Existing GCS inhibitors such as miglustat and eliglustat do not treat the neuropathic symptoms of diseases like Gaucher’s Disease (GD), but the Takeda team suggests that a brain-penetrant GCS inhibitor (like venglustat or Merck’s BZ1)…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: